The FDA on September 28, 2018 approved LIBTAYO® for patients with metastatic Cutaneous Squamous Cell Carcinoma (CSCC) or locally advanced CSCC, who are not candidates for curative surgery or curative radiation. LIBTAYO® is a product of Regeneron Pharmaceuticals Inc.
Bottom Ad
Advertisement
Subscribe
